Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive Acyclovir in Ventilated Patients with HSV Reactivation
NCT06217406Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Randomised, double-blind trial in herpes simplex virus infection comparing Acyclovir Arm with Placebo Arm (2 arms). Primary endpoint: Mortality at Day 60. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
aciclovir
03
Conditions
herpes simplex virus infection
Beyond the preview
Go deeper on NCT06217406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217406.